Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide for Lupus-associated Skin Lesions in CLE or SLE
NCT03260166Phase 2Unknown
- Sponsor
- The Second Xiangya Hospital
- Start
- Aug 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nicotinamide in cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), sponsored by The Second Xiangya Hospital. Primary endpoint: Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index activity score at 3 months. Status: unknown.
02
Drugs
nicotinamide
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03260166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03260166.